bluebird bio Inc

BLUE
1,2899
-0,0751 (-5,50%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 23:01:42
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/3/202412:01BWbluebird bio Reports Fourth Quarter and 2023 Annual Results..
25/3/202421:05BWbluebird bio to Host Fourth Quarter and 2023 Annual Results..
18/3/202413:00BWbluebird bio Secures up to $175 Million Debt Financing with..
11/3/202413:00BWbluebird bio Announces First Outcomes-Based Agreement with..
05/3/202423:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202423:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202419:54EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202422:35EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202414:03EDGAR2Form 8-K - Current report
08/1/202414:00BWbluebird bio Provides Update on Commercial Launch Progress,..
04/1/202414:00EDGAR2Form 8-K - Current report
02/1/202414:00BWbluebird bio to Present at the 42nd Annual J.P. Morgan..
20/12/202323:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/12/202313:42EDGAR2Form 8-K - Current report
20/12/202303:41BWbluebird bio, Inc. Announces Pricing of $125 Million Public..
19/12/202312:10IHMARKETNEWSGoogle $700M Antitrust Settlement, TSMC Chairman Retirement,..
18/12/202323:07EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/12/202322:48EDGAR2Form 8-K - Current report
18/12/202322:01BWbluebird bio, Inc. Announces Proposed Public Offering of..
14/12/202313:30EDGAR2Form 8-K - Current report
11/12/202314:06EDGAR2Form 8-K - Current report
10/12/202318:02BWLong-Term Data Presented at ASH Support beti-cel as a..
09/12/202317:31BWLong-term Follow-up Data From bluebird’s Gene Therapy..
08/12/202322:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/12/202322:11DJNBluebird Bio Shares Slide 41% on Black-Box Label, Higher..
08/12/202319:01BWbluebird bio Details Plans for the Commercial Launch of..
08/12/202318:35BWbluebird bio Announces FDA Approval of LYFGENIA™..
08/12/202318:03DJNBluebird Bio Gets FDA OK of Lyfgenia Gene Therapy in..
07/11/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:01EDGAR2Form 8-K - Current report
07/11/202313:00BWbluebird bio Reports Third Quarter 2023 Financial Results..
03/11/202321:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/11/202321:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/11/202314:37BWbluebird bio to Present New and Updated Data from Gene..
30/10/202313:05EDGAR2Form 8-K - Current report
30/10/202313:00BWbluebird bio Enters into Advance Agreement to Sell Priority..
24/10/202314:00BWbluebird bio to Host Third Quarter 2023 Financial Results..
27/9/202313:00EDGAR2Form 8-K - Current report
06/9/202322:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/9/202322:05BWbluebird bio Announces September Investor Events
16/8/202313:00BWbluebird bio Confirms That FDA Has Communicated That..
10/8/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 1,34 Min: 1,25 Max: 1,42
Chiusura: 1,365

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network